SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter and consumer care products to improve men’s and women's health and respiratory diseases, announced today that the Company has acquired four branded topical products from Boston Topicals, LLC (“Boston Topicals”), expanding its retail and e-commerce presence in the Company’s current highest revenue grossing category.
The products include the diabetic retail category flagship HealthiFeet®, a foot cream, with a published double-blind controlled trial shown to increase temperature and blood flow in feet of diabetic patients and formulated with the KNOSIS™ transdermal delivery system. Innovus Pharma currently plans to launch the products in its sales and marketing platforms in either the fourth quarter 2018 or the first quarter 2019.
“We continue to bolster our product pipeline with clinically and commercially validated products that fit both our direct to consumer channels as well as retail stores,” said Dr. Damaj, President and CEO of Innovus Pharma.
“HealthiFeet® is an excellent candidate for our Beyond Human® sales and marketing platform,” said Chris Stella, Vice President of Operations at Innovus Pharma. “We’ve seen tremendous success in this product category with Diabasens®, a leg and foot relief topical product, which may exceed approximately $4.5 million in annual revenue this year. We are currently projecting HealthiFeet® to become another leader in this space. It also fits well in retail stores where the product has proven to be a category leader with pilot runs at Walmart, CVS and Walgreens and with wholesalers such as McKesson and Cardinal, in which it has had over $1.6 million in cumulative sales,” he continued.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Boston Topicals’ products and other products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.